Recent Advances in Mineral and Bone Disorders in CKD (2018)
Topic 16 – Recent advances in Mineral and Bone Disorders in CKD (2018)
By Dr. Rosemary Stolzer-Bolton, DVM, DVM·20 min read··Print Article
According to Dr. Rosemary Stolzer-Bolton, DVM, a licensed DVM, at drrosiedvm.com, regarding "Recent Advances in Mineral and Bone Disorders in CKD (2018)": Topic 16 – Recent advances in Mineral and Bone Disorders in CKD (2018) For more expert veterinary guidance, visit drrosiedvm.com.
Topic 16 – Recent advances in Mineral and Bone Disorders in CKD (2018)
Henk van den Broek & Jonathan Elliott
, London, UK
Hyperphosphatemia is a well-known risk factor for disease progression and survival in cats and dogs with chronic kidney disease (CKD), and multiple studies have shown the beneficial effects of reducing the serum phosphate concentration by feeding phosphate-restricted clinical renal diets to these animals (Elliott et al., 2000; Jacob et al., 2002; Plantinga et al., 2005; Ross et al., 2006; Boyd et al., 2008; Chakrabarti et al., 2012). Reduced capacity of diseased kidneys to excrete sufficient phosphate on a daily basis as a consequence of CKD is thought to underlie the biochemical abnormalities of calcium-phosphate homeostasis, bone disease, and soft tissue calcification that are grouped together as chronic kidney disease-mineral and bone disorder (CKD-MBD) (Moe et al., 2006; Slatopolsky 2011). For decades the disturbances in calcium-phosphate homeostasis observed in patients with CKD and its consequences have been explained by hyperphosphatemia and (patho)-physiological increases in parathyroid hormone (PTH), i.e. secondary renal hyperparathyroidism, but recent advances in the understanding of phosphate homeostasis have been made by the discoveries of the phosphaturic hormone fibroblast growth factor 23 (FGF23) and its co-receptor, α-Klotho. Recognition of the role of magnesium in CKD-MBD is another recent breakthrough in the field of nephrology.
Fibroblast growth factor 23
The hormone FGF23 is released by osteocytes (Pereira et al., 2009) and decreases the serum concentration of phosphate by downregulating the membrane abundance of the sodium-dependent phosphate transporters (NaPi2a) in the proximal tubules, thus limiting reabsorption of phosphate from the tubular fluid, and by inhibiting the enzyme 1α-hydroxylase which activates vitamin D, hence reducing the serum concentration of calcitriol and thus the intestinal absorption of phosphate (Shimada et al., 2004a; Shimada et al., 2004b). To bind to its receptor and have its effects, FGF23 requires a co-factor, α-Klotho protein (Urakawa et al., 2006; Nakatani et al., 2009). The renal expression of α-Klotho is thought to reduce in CKD, thereby limiting the effects of FGF23 on phosphate excretion (Sakan et al., 2014). No studies have been published yet on the expression of α-Klotho in veterinary patients with CKD, but multiple studies have investigated FGF23 in cats and dogs with CKD.
FGF23 and CKD IRIS Stage
In cats, plasma FGF23 increases in the early stages of CKD before the occurrence of overt azotemia (Finch et al., 2013) and the plasma concentration of FGF23 increases considerably with IRIS CKD stage from a median concentration of 354 pg/mL in IRIS Stage 2 to 1282 pg/mL in Stage 3 and 33478 pg/mL in Stage 4 CKD (Geddes et al., 2013a).
Dogs with CKD also have significantly increased plasma FGF23 concentrations compared to healthy dogs (Dittmer et al., 2017), but this is predominantly true for the IRIS stage 3 and 4 CKD (Harjes et al., 2017). Plasma FGF23 concentration increased in dogs with CKD from a median of 336 pg/mL in IRIS CKD Stage 2, to 2302 pg/mL in Stage 3 and 7733 pg/mL in Stage 4 CKD (Harjes et al., 2017).
FGF23 and hyperphosphatemia
Cats that are hyperphosphatemic in relation to their IRIS stage have significantly higher plasma FGF23 concentrations than normophosphatemic cats with the same severity of CKD (Geddes et al., 2013a). This could not be clearly established in dogs with CKD, probably due to the low numbers of dogs included in each group in this study (Harjes et al., 2017). However, both in cats and dogs with CKD, a significant correlation between plasma FGF23 and phosphate concentrations has been identified (Geddes et al., 2013a; Dittmer et al., 2017). Moreover, feeding a phosphate restricted renal diet was associated with a decrease in plasma FGF23, both in hyperphosphatemic and normophosphatemic cats with stable azotemic CKD (Geddes et al., 2013b). Plasma FGF23 might therefore be used to monitor the effect of treatment in cats with CKD. The effect of dietary phosphate restriction on plasma FGF23 concentrations in dogs with CKD has not yet been examined.
FGF23 and survival
In cats, higher plasma FGF23 concentrations at diagnosis of CKD have been associated with increased risk of death (Geddes et al., 2015, Van den Broek et al., 2018). In the retrospective study by Geddes et al. (2015) on 214 cats with CKD, cats with plasma FGF23 >3000 pg/mL had statistically significant decreased survival compared to cats with plasma FGF23 below the upper limit of its proposed reference interval (i.e. 700 pg/mL) at diagnosis of azotemic CKD, independent of their IRIS stage or age (Geddes et al., 2015). Cats with plasma FGF23 concentrations < 700 pg/mL had a median survival time of 577 days from diagnosis of azotemic CKD, whilst cats with plasma FGF23 concentrations between 3000 and 10,000 pg/mL had a median survival of 277 days Geddes et al., 2015). Median survival time decreased further to 38 days in cats with plasma FGF23 > 10,000 pg/mL at diagnosis of CKD.
A prospective survival study on 27 dogs with variable stages of CKD found a statistically significant increased risk of death for dogs with plasma FGF23 >450 pg/mL compared to dogs with plasma FGF23 <450 pg/mL. (Rudinsky et al., 2018) Dogs with plasma FGF23 <450 pg/mL had a median survival of 26 months, whilst dogs with plasma FGF23 >450 pg/mL had a median survival of 10 months, however multivariable analysis was not performed due to the low number of dogs enrolled onto this study (Rudinsky et al., 2018).
The mechanisms accounting for the association between FGF23 and decreased survival have not been investigated in cats and dogs, but in humans FGF23 excess has been associated with left ventricular hypertrophy, anemia and inflammation (Faul et al., 2011; Scialla et al., 2014; Singh et al., 2016; Mehta et al., 2017).
FGF23 and progression of CKD
In cats, higher plasma FGF23 concentration has been identified as an independent predictor of disease progression within the first 12 months following diagnosis of azotemic CKD (Geddes et al., 2015; Van den Broek et al., 2018). In the study by Geddes et al. (2015) cats that showed a plasma creatinine increase >25% within a year of diagnosis had a median baseline plasma FGF23 concentration of 1243 pg/mL, whilst cats with stable disease had a median concentration of 504 pg/mL.
Plasma FGF23 is elevated prior to the development of overt renal azotemia in cats. Finch et al. (2013) showed that plasma FGF23 concentration was significantly higher in non-azotemic cats that progressed to azotemic CKD within a 12-month follow-up period than in cats that remained non-azotemic (Finch et al., 2013). Such observations have not been reported for dogs.
Measuring FGF23
Intact FGF23 can be measured by a sandwich-ELISA (Kainos, Tokyo, Japan) in a small volume (0.1 mL) of heparinized plasma, although currently this test is not clinically available. In geriatric cats the reference interval generated for the plasma concentration of FGF23 appears much higher than in humans: 56-700 pg/mL compared to 8.2-54.3 pg/mL (Geddes et al., 2013a). In the abovementioned study by Finch et al. (2013), cats that remained non-azotemic over a 12-month period generally had plasma FGF23 concentrations below 200 pg/mL, which suggests that the reference interval upper limit for FGF23 in cats of 700 pg/mL is too high. In dogs, no reference interval has been established, but the upper plasma FGF23 concentration from healthy dogs (i.e. 449 pg/mL) has been used as the cutoff value to define FGF23 excess in this species (Harjes et al., 2017).
Magnesium
Magnesium is an important mineral for various physiologic processes, such as ATP generation and bone formation, and an inhibitor of soft tissue calcification (Jahnen-Dechent & Ketteler, 2012; Louvet et al., 2013). It is primarily stored in bone and muscle tissue, and only 1% of the total body magnesium stores is located in serum, in which it can be found in 3 fractions: ionized, protein-bound, and complexed with anions (Elin, 2010; Jahnen-Dechent & Ketteler, 2012; Humphrey et al., 2014).
Magnesium and CKD IRIS stage
Plasma total magnesium concentrations are relatively stable in cats with IRIS stage 2 and 3 CKD, and becomes elevated when renal excretory function is severely impaired in IRIS stage 4 CKD (Barber & Elliott, 1998; Van den Broek et al., 2018). In our recent study involving 174 cats with azotemic CKD, we identified hypomagnesemia (defined as serum total magnesium concentration <0.71 mmol/l) in 9%, 18% and 10% of cats with IRIS stage 2, 3, and 4 CKD, respectively (Van den Broek et al., 2018). Hypermagnesemia was only identified in 3% of cats with IRIS stage 2 CKD and 6% of cats with IRIS stage 3 CKD, but in 50% of cats with IRIS stage 4 CKD. Information on ionized magnesium was unavailable (Van den Broek et al., 2018).
Magnesium and FGF23
In human hemodialysis patients, an inverse relationship between serum magnesium and FGF23 concentrations has been observed (Iguchi et al., 2014). We had very similar findings in cats with azotemic CKD, in which plasma total magnesium concentrations were inversely associated with plasma FGF23 concentrations in each CKD IRIS stage (Van den Broek et al., 2018). Rodent studies suggest that dietary magnesium intake influences plasma FGF23 concentrations (Matsuzaki et al., 2013). Dietary magnesium supplementation could potentially be an additional management strategy to lower plasma FGF23, just as dietary phosphate restriction is efficient in reducing plasma FGF23 concentrations (Geddes et al., 2013b).
Magnesium and survival
Various observational studies have identified hypomagnesemia (based on serum total magnesium) as a risk factor for death in human patients with dialysis-dependent CKD and non dialysis-dependent CKD (Ishimura et al., 2007; Kanbay et al., 2012; Van Laecke et al., 2013; Sakaguchi et al., 2014a). Moreover, higher serum magnesium appears to attenuate the mortality risk associated with hyperphosphatemia in human CKD patients (Sakaguchi et al., 2014b). In cats, hypomagnesemia at diagnosis of azotemic CKD was also significantly associated with an increased risk of death, independent of age, packed cell volume, plasma FGF23, and severity of CKD and proteinuria (Van den Broek et al., 2018). Our results also suggested that higher plasma magnesium attenuates the risk of death associated with hyperphosphatemia in cats, as it does in humans, but this observation needs further investigation.
Hypermagnesemia was also associated with an increased risk of death, but not after correction for CKD IRIS stage. Therefore, this association was likely due to the increased prevalence of hypermagnesemia in cats with end-stage CKD (Van den Broek et al., 2018).
In unadjusted analysis, hypomagnesemia was not only associated with reduced survival but also with increased risk of progression of azotemia (Van den Broek et al., 2018). This association was lost, however, after correction for other variables and further studies are required to assess this possible association.
Measuring magnesium
Plasma total magnesium can be measured by most laboratories in patient serum or heparinized plasma samples, but EDTA plasma needs to be avoided as it will lead to an erroneously low result (Sharratt et al., 2009). Ionized magnesium is biologically-active and therefore might reflect magnesium status better than total magnesium (Bateman, 2012; Humphrey et al., 2014). However, there is no consensus whether total or ionized magnesium best reflects body magnesium status and the current knowledge derived from the studies on humans and cats presented above is based on measurement of total magnesium. We derived a reference interval for plasma total magnesium from 120 apparently-healthy senior cats of 1.73-2.57 mg/dL or 0.71-1.06 mmol/L (Van den Broek et al., 2018).
Bone disease and soft tissue calcification
The clinical focus in veterinary medicine has mainly been on the biochemical abnormalities associated with CKD in cats and dogs. Less attention has been paid to bone disease (i.e. renal osteodystrophy) and soft tissue calcification, which do occur in cats and dogs with CKD - albeit in the more advanced stages of disease. Osteitis fibrosa cystica and bone resorption most likely occur as a result of high bone turnover caused by secondary renal hyperparathyroidism, and have been reported in early radiographic and necropsy studies in cats with CKD (Lucke, 1968; DiBartola et al., 1987). In dogs, osteodystrophy affecting the maxillofacial and mandible bones, and ultimately "rubber jaw" is observed (Davis, 2015). Two recent studies using micro-CT compared the bone structure of cats and dogs with CKD to that of healthy controls. Bones of cats with IRIS Stage 3 and 4 CKD had decreased mineral density and an increased cortical porosity (Shipov et al., 2014). A similar study on dogs found relatively mild changes in bone quality in animals with CKD, which is probably due to the shorter duration of disease in dogs compared to that of cats and humans (Shipov et al., 2018).
Vascular calcification, by the deposition of calcium phosphate salts in the medial layer of the vessel wall, is an important predictor of patient mortality due to cardiovascular disease in human CKD patients (London et al., 2003; Górriz et al., 2015). Increases in serum phosphate and calcium stimulate calcification of vessel walls, which leads to increased vascular stiffness, elevated pulse pressure and left ventricular hypertrophy (London et al., 2003; Lomashvili et al., 2006; Shanahan et al., 2011). In cats, radiographic evidence exists for soft tissue calcification of the thoracic and abdominal aorta, as well as of other soft tissues such as the gastric wall, kidneys and interdigital space (DiBartola et al., 1987; Jackson & Barber, 1998; Bertazzolo et al., 2003; Chakrabarti et al., 2013; McLeland et al., 2014). Chronic kidney disease leads to an imbalance of serum promotors (e.g. phosphate, calcium) and inhibitors (e.g. magnesium, fetuin-A) of calcification, and the effects of these imbalances on the propensity of individual patient's serum to calcify can be measured by an assay, the T50 test (Pasch et al., 2012). Increased serum calcification propensity has been associated with increased risk of death and mineral imbalances in humans with CKD (Smith et al., 2014; Bielesz et al., 2017). Recently, we presented data showing that more severe CKD-MBD appears associated with an increased tendency of individual cat's serum to calcifya. Whether vascular calcification is of clinical significance and what its relationship is to systemic arterial hypertension in dogs and cats with CKD is unknown.
In conclusion, the importance of restricting dietary phosphate intake in the CKD patient has been recognized for many years and is a key component of the management of CKD in veterinary and human medicine. Recent advances in understanding the role of FGF23 - α-Klotho axis in the pathophysiology of bone and mineral disorders associated with chronic kidney disease and recognition of the way in which serum magnesium impacts on this hormonal system and influences the propensity for vascular calcification are important. Routine measurement of serum FGF23 and magnesium could identify those veterinary patients that will benefit most from effective management of these bone mineral disturbances.
a (Van den Broek, D.H.N., Chang, Y.-M., Elliott, J., and Jepson, R.E. (2018) Serum calcification propensity in cats with chronic kidney disease. Abstract presented at ACVIM Forum 2018, Seattle, USA)
References
Barber PJ, Elliott J. Feline chronic renal failure: calcium homeostasisin 80 cases diagnosed between 1992 and 1995. Journal of Small Animal Practice 1998;39:108-116.
Bateman S. Disorders of magnesium: magnesium deficit and excess. In: DiBartola SP, ed.Fluid, electrolyte, and acid-base disorders in small animal practice. St. Louis, MI: Elsevier Saunders; 2012:212-229.
Bertazzolo W, Toscani L, Calcaterra S, et al. Clinicopathological findings in five cats with paw calcification. Journal of Feline Medicine and Surgery 2003;5:11-17.
Bielesz B, Reiter T, Marculescu R, et al. Calcification Propensity of Serum is Independent of Excretory Renal Function. Scientific Reports 2017;7:17941.
Boyd LM, Langston C, Thompson K, Zivin K, Imanishi M. Survival in cats with naturally occurring chronic kidney disease (2000-2002). Journal of Veterinary Internal Medicine 2008;22:1111-1117.
Chakrabarti S, Syme HM, Elliott J. Clinicopathological variables predicting progression of azotemia in cats with chronic kidney disease. Journal of Veterinary Internal Medicine 2012;26:275-281.
Chakrabarti S, Syme HM, Brown CA, et al. Histomorphometry of feline chronic kidney disease and correlation with markers of renal dysfunction. Veterinary Pathology 2013;50:147-155.
Davis EM. Oral manifestations of chronic kidney disease and renal secondary hyperparathyroidism: a comparative review. Journal of Veterinary Dentistry 2015;32:87-98
DiBartola SP, Rutgers HC, Zack PM, et al. Clinicopathologic findings associated with chronic renal disease in cats: 74 cases (1973-1984). Journal of the American Veterinary Medical Association 1987;190:1196-1202.
Dittmer KE, Perera KC, Elder PA. Serum fibroblast growth factor 23 concentrations in dogs with chronic kidney disease. Research in Veterinary Science 2017:114: 348-350.
Elin RJ. Assessment of magnesium status for diagnosis and therapy. Magnesium Research 2010; 23:S194-8.
Elliott J, Rawlings JM, Markwell PJ, et al. Survival of cats with naturally occurring chronic renal failure: effect of dietary management. The Journal of small animal practice 2000;41:235-242.
Faul C, Amaral AP, Oskouei B, et al. FGF23 induces left ventricular hypertrophy. Journal of Clinical Investigation 2011;121:4393-4408.
Finch NC, Geddes RF, Syme HM, et al. Fibroblast growth factor 23 (FGF-23) concentrations in cats with early nonazotemic chronic kidney disease (CKD) and in healthy geriatric cats. Journal of Veterinary Internal Medicine 2013;27:227-233.
Geddes RF, Finch NC, Elliott J, et al. Fibroblast growth factor 23 in feline chronic kidney disease. Journal of Veterinary Internal Medicine 2013a;27:234-241.
Geddes R, Elliott J, Syme H. The effect of feeding a renal diet on plasma fibroblast growth factor 23 concentrations in cats with stable azotemic chronic kidney disease. Journal of Veterinary Internal Medicine 2013b;27:1354-1361.
Geddes R, Elliott J, Syme H. Relationship between plasma fibroblast growth factor–23 concentration and survival time in cats with chronic kidney disease. Journal of Veterinary Internal Medicine 2015;29:1494-1501.
Górriz JL, Molina P, Cerverón MJ, et al. Vascular Calcification in Patients with Nondialysis CKD over 3 Years. Clinical Journal of the American Society of Nephrology 2015.
Harjes L, Parker V, Dembek K, Young G, Giovaninni L, Kogika M, Chew D, Toribio R. Fibroblast Growth Factor–23 concentration in dogs with chronic kidney disease. Journal of Veterinary Internal Medicine 2017:31:784-790.
Humphrey S, Kirby R, Rudloff E. Magnesium physiology and clinical therapy in veterinary critical care. Journal of Veterinary Emergency and Critical Care 2015;25: 210-225.
Iguchi A, Watanabe Y, Iino N, et al. Serum magnesium concentration is inversely associated with fibroblast growth factor 23 in haemodialysis patients.Nephrology 2014;19:667-671.
Ishimura E, Okuno S, Yamakawa T, Inaba M, Nishizawa Y. Serum magnesium concentration is a significant predictor of mortality in maintenance hemodialysis patients. Magnesium Research 2007;20:237-244.
Jackson HA, Barber PJ. Resolution of metastatic calcification in the paws of a cat with successful dietary management of renal hyperparathyroidism. The Journal of Small Animal Practice 1998;39:495-497.
Jacob F, Polzin DJ, Osborne CA, et al. Clinical evaluation of dietary modification for treatment of spontaneous chronic renal failure in dogs. Journal of the American Veterinary Medical Association 2002;220:1163-1170.
Jahnen-Dechent W, Ketteler M. Magnesium basics. Clinical Kidney Journal 2012;5:i3-i14.
Kanbay M, Yilmaz MI, Apetrii M, et al. Relationship between serum magnesium levels and cardiovascular events in chronic kidney dis-ease patients. American Journal of Nephrology 2012;36:228-237.
Lomashvili K, Garg P, O'Neill WC. Chemical and hormonal determinants of vascular calcification in vitro. Kidney International 2006;69:1464-1470.
London GM, Guérin AP, Marchais SJ, et al. Arterial media calcification in end-stage renal disease: impact on all-cause and cardiovascular mortality. Nephrology Dialysis Transplantation 2003;18:1731-1740.
Louvet L, Buchel J, Steppan S, et al.. Magnesium prevents phosphate-induced calcification in human aortic vascular smooth muscle cells. Nephrology Dialysis Transplantation 2013;28:869-878.
Lucke VM. Renal disease in the domestic cat. The Journal of Pathology and Bacteriology 1968;95:67-91.
Matsuzaki H, Kajita Y, Miwa M. Magnesium deficiency increases serum fibroblast growth factor-23 levels in rats. Magnesium Research 2013;26:18-23.
McLeland SM, Lunn KF, Duncan CG, et al. Relationship among serum creatinine, serum gastrin, calcium-phosphorus product, and uremic gastropathy in cats with chronic kidney disease. Journal of Veterinary Internal Medicine 2014;28:827-837.
Mehta R, Cai X, Hodakowski A. Fibroblast growth factor 23 and anemia in the Chronic Renal Insufficiency Cohort Study. Clinical Journal of the American Society of Nephrology 2017;12:1795-1803.
Moe S, Drueke T, Cunningham J, et al. Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney International 2006;69:1945-1953.
Nakatani T, Ohnishi M, Razzaque MS. Inactivation of klotho function induces hyperphosphatemia even in presence of high serum fibroblast growth factor 23 levels in a genetically engineered hypophosphatemic (Hyp) mouse model. FASEB Journal 2009;23:3702-3711.
Pasch A, Farese S, Graber S, et al. Nanoparticle-based test measures overall propensity for calcification in serum. Journal of the American Society of Nephrology 2012;23:1744-1752.
Pereira RC, Juppner H, Azucena-Serrano CE, et al. Patterns of FGF-23, DMP1, and MEPE expression in patients with chronic kidney disease. Bone 2009; 45:1161-1168.
Plantinga EA, Everts H, Kastelein AM, et al. Retrospective study of the survival of cats with acquired chronic renal insufficiency offered different commercial diets. The Veterinary Record 2005;157:185-187.
Ross SJ, Osborne CA, Kirk CA, et al. Clinical evaluation of dietary modification for treatment of spontaneous chronic kidney disease in cats. Journal of the American Veterinary Medical Association 2006;229:949-957.
Rudinsky AJ, Harjes LM, Byron J, et al. Factors associated with survival in dogs with chronic kidney disease. Journal of Veterinary Internal Medicine 2018;32:1864-1873.
Sakaguchi Y, Fujii N, Shoji T, et al.. Hypomagnesemia is a significant predictor of cardiovascular and non-cardiovascular mortality in patients undergoing hemodialysis. Kidney International 2014a;85:174-181.
Sakaguchi Y, Fujii N, Shoji T, et al. Magnesium modifies the cardio-vascular mortality risk associated with hyperphosphatemia in patients undergoing hemodialysis: a cohort study. PLoS One.2014;9:e116273.
Sakan H, Nakatani K, Asai O, Imura A, Tanaka T, et al. Reduced Renal α-Klotho Expression in CKD Patients and Its Effect on Renal Phosphate Handling and Vitamin D Metabolism. PLOS ONE 2014:9:e86301.
Scialla JJ, Xie H, Rahman M., et al. Fibroblast growth factor-23 and cardiovascular events in CKD. Journal of the American Society of Nephrology, 2014;25:349-360.
Shanahan CM, Crouthamel MH, Kapustin A, et al. Arterial calcification in chronic kidney disease: key roles for calcium and phosphate. Circulation Research 2011;109:697-711.
Sharrat CL, Gilbert CJ, Cornes MC et al. EDTA sample contamination is common and often undetected, putting patients at unnecessary risk of harm. International Journal of Clinical Practice 2009;63:1259-1262.
Shimada T, Hasegawa H, Yamazaki Y, et al. FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis. Journal of Bone and Mineral Research 2004a;19:429-435.
Shimada T, Kakitani M, Yamazaki Y, et al. Targeted ablation of Fgf23 demonstrates an essential physiological role of FGF23 in phosphate and vitamin D metabolism. The Journal of Clinical Investigation 2004b;113:561-568.
Shipov A, Segev G, Meltzer H, et al. The effect of naturally occurring chronic kidney disease on the micro-structural and mechanical properties of bone. PloS one 2014;9:e110057.
Shipov A, Shahar R, Sugar N, Segev G. The Influence of Chronic Kidney Disease on the Structural and Mechanical Properties of Canine Bone. Journal of Veterinary Internal Medicine 2018;32:280-287.
Singh S, Grabner A, Yanucil C, et al. Fibroblast growth factor 23 directly targets hepatocytes to promote inflammation in chronic kidney disease. Kidney International 2016;90:985-996.
Slatopolsky E. The intact nephron hypothesis: the concept and its implications for phosphate management in CKD-related mineral and bone disorder. Kidney International Supplement 2011:S3-8.
Smith ER, Ford ML, Tomlinson LA, et al. Serum calcification propensity predicts all-cause mortality in predialysis CKD. Journal of the American Society of Nephrology 2014;25:339-348.
Urakawa I, Yamazaki Y, Shimada T, et al. Klotho converts canonical FGF receptor into a specific receptor for FGF23. Nature 2006;444:770-774.
Van den Broek DHN, Chang Y–M, Elliott J, Jepson RE. Prognostic importance of plasma total magnesium in a cohort of cats with azotemic chronic kidney disease. Journal of Veterinary Internal Medicine 2018;32:1359-1371.
Van Laecke S, Nagler EV, Verbeke F, et al. Hypomagnesemia and the risk of death and GFR decline in chronic kidney disease. American Journal of Medicine 2013;126:825-831.
This content is for educational purposes only and is not a substitute for professional veterinary advice, diagnosis, or treatment. Always consult your veterinarian with any questions about your pet's health.
Frequently Asked Questions
What is Topic 16 – Recent advances in Mineral and Bone Disorders in CKD (2018)?
Topic 16 – Recent advances in Mineral and Bone Disorders in CKD (2018)
What should pet owners know about topic 16 – recent advances in mineral and bone disorders in ckd (2018)?
Hyperphosphatemia is a well-known risk factor for disease progression and survival in cats and dogs with chronic kidney disease (CKD), and multiple studies have shown the beneficial effects of reducing the serum phosphate concentration by feeding phosphate-restricted clinical renal diets to these animals (Elliott et al., 2000; Jacob et al., 2002; Plantinga et al., 2005; Ross et al., 2006; Boyd et al., 2008; Chakrabarti et al., 2012).
How is topic 16 – recent advances in mineral and bone disorders in ckd (2018) treated in pets?
Cats that are hyperphosphatemic in relation to their IRIS stage have significantly higher plasma FGF23 concentrations than normophosphatemic cats with the same severity of CKD (Geddes et al., 2013a). This could not be clearly established in dogs with CKD, probably due to the low numbers of dogs included in each group in this study (Harjes et al., 2017).
Stay in the Loop
Get the latest veterinary insights, new videos, and exclusive content delivered to your inbox.
